key: cord-0723471-wjl49ie2
authors: Abrams, Joseph Y.; Godfred-Cato, Shana E.; Oster, Matthew E.; Chow, Eric J.; Koumans, Emilia H.; Bryant, Bobbi; Leung, Jessica W.; Belay, Ermias D.
title: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review
date: 2020-08-05
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.08.003
sha: 4313ffbcbfa228b9dded62865856cd8a893f3b29
doc_id: 723471
cord_uid: wjl49ie2

OBJECTIVE: To develop a more comprehensive description of multisystem inflammatory syndrome in children (MIS-C), a novel syndrome linked to SARS-CoV-2, by conducting a systematic analysis of studies from different settings which used various inclusion criteria. STUDY DESIGN: MIS-C studies were identified by searching PubMed and Embase as well as preprint repositories and article references to identify studies of MIS-C cases published from April 25, 2020 through June 29, 2020. MIS-C study metadata were assessed and information on case demographics, clinical symptoms, laboratory measurements, treatments, and outcomes were summarized and contrasted between studies. RESULTS: Eight studies were identified representing a total of 440 MIS-C cases. Inclusion criteria varied by study: three studies selected patients diagnosed with Kawasaki disease (KD), two required cardiovascular involvement, and three had broader multisystem inclusion criteria. Median age of patients by study ranged from 7.3 to 10 years, and 59% of patients were male. Across all studies, the proportion of patients with positive results for SARS-CoV-2 RT-PCR tests ranged from 13 to 69% and for serology, from 75 to 100%. MIS-C patients had high prevalence of gastrointestinal (87%), dermatologic/mucocutaneous (73%), and cardiovascular (71%) symptoms. Prevalence of cardiovascular, neurologic, and respiratory system involvement significantly differed by study inclusion criteria. All studies reported elevated C-reactive protein, interleukin-6, and fibrinogen levels for at least 75% of patients in each study. CONCLUSIONS: This systematic review of MIS-C studies assists with understanding this newly identified syndrome and may be useful in developing a refined, universal case definition of MIS-C.

Literature searches were conducted using PubMed and Embase for papers published from April 25, 2020 through June 29, 2020. Given the novelty of MIS-C, preprint manuscripts uploaded to medRxiv and bioRxiv servers during the same timeframe were also searched. Due to the rapidly evolving understanding of MIS-C, a variety of search terms were utilized to identify reports of MIS-C cases. The search terms included the following phrases or combinations of phrases "multisystem inflammatory syndrome"; "kawasaki disease"; "hyperinflammatory"; "hyperinflammation"; "toxic shock syndrome"; "shock" with "children" or "pediatric"; "cytokine" with "children" or "pediatric"; "inflammation" or "inflammatory" with "syndrome" and "children" or "pediatric."

Studies on MIS-C cases have used different names for the syndrome and used different criteria to identify cases. To ensure that no studies were missed through keyword searches, Google Scholar was used to search through any studies that cited two early, impactful publications on MIS-C. (7, 10) Papers identified through all searches were examined to determine if they were studies describing patients with clinical and epidemiologic characteristics consistent with MIS-C as defined by the UK Royal College of Paediatrics and Child Health (RCPCH), New York State Department of Health, the US Centers for Disease Control and Prevention (CDC), (11) or the WHO.(12) Studies describing patients fitting the following criteria were included in the analysis:1) young age (typically under 21 years old); 2) severe cardiovascular or multisystem clinical manifestations; 3) laboratory evidence of inflammation; 4) either laboratory evidence of SARS-CoV-2 infection or epidemiological association with COVID-19 (including temporal association with periods of high local COVID-19 transmission).

Additionally, given the substantial clinical overlap between MIS-C and KD, another syndrome without a J o u r n a l P r e -p r o o f diagnostic test, studies describing KD patients with laboratory or epidemiologic links to SARS-CoV-2 were included in this systematic review.

Only studies that described at least 5 MIS-C cases were included, and studies with MIS-C patients largely or entirely described in other publications were excluded. We used information on setting (dates of case identification and healthcare setting) to identify potential duplication of patients between studies, following up with study authors for additional information. Data collected from the papers included: case inclusion criteria, demographic information, clinical signs/symptoms and outcomes, laboratory markers of inflammation and cardiovascular function, and treatments administered. Studies that did not sufficiently describe the above data were excluded. Median and interquartile range (IQR) for laboratory values were captured if reported by each study, along with the proportion of patients with abnormal values using reference ranges reported for each study. For studies that reported median and IQR but not the proportion with abnormal values, the range of possible proportions was reported based on which percentile values fell outside reference ranges (For example, if the reported 25 th percentile was within the reference range but the median was above it, we know that between 50-75% of patients in the study had elevated values for that marker).

Studies were divided into three categories based on inclusion criteria; studies with cardiovascular involvement as a requirement for inclusion; patients meeting KD clinical case definition(13) as a requirement for inclusion; and broader criteria that captured patients with multisystem involvement along with evidence of inflammation and links to COVID-19. Generalized linear mixed models with double arcsine-transformed proportions (14) were used to assess differences in prevalence of clinical symptoms and treatments administered by study category. The mixed model approach allowed for the comparison of proportions by inclusion criteria while accounting for study heterogeneity. Eight published studies were included in this systematic review that captured a total of 440 patients. (8, 10, 21, 22, 28, 29, 31, 32) ( Table I ). The total number of patients included in the studies ranged from 10 to 186. The two largest studies were from the US, and the other six studies were from European countries. Primary inclusion criteria for three of the European studies (one from Italy and two from France) was a diagnosis of KD. (10, 28, 31) Two studies required cardiovascular system involvement: one study from the UK(29) selected children referred for cardiovascular evaluation and who met the UK RCPCH criteria for MIS-C; (33) another study in France and Switzerland identified children with acute left ventricular systolic dysfunction or cardiogenic shock along with an associated multisystem inflammatory state. (8) Two studies from the US (21, 22) and one from the UK(32) used broader inclusion criteria which included fever, multisystem involvement, and laboratory evidence of J o u r n a l P r e -p r o o f inflammation; the US studies also required laboratory or epidemiologic link to COVID-19. Full inclusion criteria for each study are detailed in the Appendix [available at www.jpeds.com.

Median age of patients by study ranged from 7.3 to 10 years, and 59% of all patients (43%-73% across studies) were male. In the six studies that reported race/ethnicity data, the proportion of black or Afro-Caribbean patients ranged from 31 to 62%. The two US studies reported Hispanic ethnicity, which followed by dermatologic/mucocutaneous symptoms (73%) and cardiovascular symptoms (71%), with fewer patients reporting respiratory (47%), neurologic (22%), and musculoskeletal (21%) symptoms.

The proportion reporting cardiovascular symptoms, neurologic symptoms, and respiratory symptoms differed by inclusion criteria. The studies which used cardiovascular inclusion criteria had a prevalence of cardiovascular symptoms of 100%, and studies selecting KD patients included higher prevalence of neurologic symptoms (55%) but lower prevalence of respiratory symptoms (14%). Figure 2 shows the proportion of patients in each study receiving different therapies. Of listed therapies, intravenous immunoglobulin (IVIG) was the most commonly administered (76% of patients) compared with vasoactive medications (53%), steroids (52%), and immune modulators (18%). In addition, 26% of patients received intubation, and 6% required extracorporeal membrane oxygenation (ECMO). IVIG was given to 98% of patients from the studies selecting KD patients. Studies using cardiovascular inclusion criteria had lower prevalence of treatment with steroids (34%) but higher prevalence of use of ECMO (20%). Table 2 summarizes laboratory test results reported by each study. In every study for which the J o u r n a l P r e -p r o o f proportion of patients with abnormal levels could be ascertained, ferritin and d-dimer levels were elevated in at least 50% of patients, and C-reactive protein, interleukin-6, and fibrinogen were elevated in each study in at least 75% of patients. Decreased platelet levels were also commonly observed in many studies. Highly elevated levels for markers of cardiac damage -troponin, brain natriuretic peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP) -were seen in the majority of patients across studies and were observed in potentially 100% of patients for the studies with cardiovascular inclusion criteria.

Our review summarizes and compares data from eight separate studies that describe patients with features with MIS-C, a substantial proportion of MIS-C cases may continue to be classified as KD as more children are exposed to SARS-CoV-2. Early reports support the use of IVIG, which is the standard treatment for KD, for use in treating MIS-C patients; (7, 9, 23) corticosteroids also have an important role in KD treatment and the same may prove true for MIS-C. (19) Despite this, there may be key etiological and pathophysiologic differences between KD and MIS-C, and distinguishing the two syndromes may be important for establishing best practices for MIS-C treatment and prevention.

In all studies, the proportion of patients with positive SARS-CoV-2 serology testing was substantially higher than of those with positive SARS-CoV-2 RT-PCR tests. These findings as well as 

World Health Organization: World Health Organization

Epidemiology of COVID-19 among children in China

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States

Coronavirus Disease 2019 in Children -United States

Increased number of reported cases of novel presentation of multi-system inflammatory disease. Paediatric Intensive Care Society: Paediatric Intensive Care Society

COVID-19 and Kawasaki Disease: Finding the Signal in the Noise

Hyperinflammatory shock in children during COVID-19 pandemic

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Centers for Disease Control and Prevention Health Alert Network 2020

Multisystem inflammatory syndrome in children and adolescents temporally related to COVID

World Health Organization

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

Transformations related to the angular and the square root

Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data

SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study

Characteristics, Cardiac involvement, and Outcomes of Multisystem Inflammatory Disease of Childhood (MIS-C) Associated with SARS-CoV-2 Infection

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series

Severe COVID-19 in children and young adults in the Washington, DC metropolitan region

Multisystem Inflammatory Syndrome in Children in New York State. The New England journal of medicine

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

Spectrum of Imaging Findings on Chest Radiographs, US, CT, and MRI Images in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection: A Multiinstitutional Study from

Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases

Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. Pediatr Cardiol. 2020. 30

Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Guidance-Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 2020

Pediatric COVID-associated Multi-system Inflammatory Syndrome (PMIS)

Kawasaki-like disease: emerging complication during the COVID-19 pandemic

Covid-19: Cases of inflammatory syndrome in children surge after urgent alert

Coronavirus Disease

COVID-19) Surveillance Report: Week 26. Public Health England

Population and Housing Unit Estimates. US Census Bureau, Population Estimates Program

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. medRxiv

Prevention CfDCa. Social Determinants of Health: Know What Affects Health: Centers for Disease Control and Prevention

Promoting Health Equity: A Resource to Help Communities Address Social Determinants of Health

COVID-19 and Racial/Ethnic Disparities

Best available treatment study for inflammatory conditions associated with COVID-19. ISRCTN Registry: Imperial College London